These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 28537449)

  • 21. A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action.
    Drab SR; Philis-Tsimikas A
    Pharmacotherapy; 2014 Mar; 34(3):291-302. PubMed ID: 24132869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.
    Clements JN; Threatt T; Ward E; Shealy KM
    Clin Pharmacokinet; 2017 May; 56(5):449-458. PubMed ID: 27699623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin.
    Josse RG; Woo V
    Diabetes Obes Metab; 2013 Dec; 15(12):1077-84. PubMed ID: 23577589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
    Owens DR; Bolli GB
    Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
    Shiramoto M; Eto T; Irie S; Fukuzaki A; Teichert L; Tillner J; Takahashi Y; Koyama M; Dahmen R; Heise T; Becker RH
    Diabetes Obes Metab; 2015 Mar; 17(3):254-60. PubMed ID: 25425297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
    Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
    Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical use of the co-formulation of insulin degludec and insulin aspart.
    Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
    Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
    Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will the next generation of basal insulins offer clinical advantages?
    Garber AJ
    Diabetes Obes Metab; 2014 Jun; 16(6):483-91. PubMed ID: 24118819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Basal insulins: Pharmacological properties and patient perspectives.
    Abrahamson MJ
    Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of the Next Generation of Long-Acting Basal Insulins: Insulin Degludec and Insulin Glargine.
    Stailey M; Conway SE
    Consult Pharm; 2017 Jan; 32(1):42-46. PubMed ID: 28077204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Insulins and New Aspects in Insulin Delivery.
    Woo VC
    Can J Diabetes; 2015 Aug; 39(4):335-43. PubMed ID: 26233724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
    Fadini GP; Feher M; Hansen TK; de Valk HW; Koefoed MM; Wolden M; Zimmermann E; Jendle J
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5977-5990. PubMed ID: 31397845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoglycemia rates with basal insulin analogs.
    Little S; Shaw J; Home P
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin degludec: a novel basal insulin analogue.
    Goldman-Levine JD; Patel DK; Schnee DM
    Ann Pharmacother; 2013 Feb; 47(2):269-77. PubMed ID: 23386075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Basal weekly insulins: the way of the future!
    Rosenstock J; Del Prato S
    Metabolism; 2022 Jan; 126():154924. PubMed ID: 34728221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
    Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
    Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.
    Rosenstock J; Juneja R; Beals JM; Moyers JS; Ilag L; McCrimmon RJ
    Endocr Rev; 2024 May; 45(3):379-413. PubMed ID: 38224978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the Pharmacokinetics and Glucodynamics of Once Weekly Basal Insulins to Inform Dosing Principles: An Introduction to Clinicians.
    Pieber TR; Leohr J; Bue-Valleskey JM; Juneja R; Chien J; Syring K; Buse JB
    Endocr Pract; 2024 Sep; 30(9):863-869. PubMed ID: 38880349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.